Celecoxib with immunotherapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a pain reliever (celecoxib) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this three-drug combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (hepatocellular carcinoma) that has spread or cannot be surgically removed.
- Your cancer is measurable on a CT scan or MRI.
- You are at least 18 years old.
- You are in generally good health (able to do daily activities, with some limitations allowed).
- Your blood counts (platelets, hemoglobin, neutrophils) and liver/kidney function meet certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) plus standard chemotherapy (gemcitabine and cisplatin) for people with a rare type of liver cancer that has spread or cannot be removed by surgery. The goal is to see if this treatment can shrink tumors and improve outcomes.
This study tests whether adding celecoxib (an anti-inflammatory drug) to standard immunotherapy and chemotherapy improves outcomes for people with a specific type of bile duct cancer that has high levels of a protein called CK5/6. It aims to see if the combination is safe and effective.
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.